胃癌患者血清肿瘤标志物CA_(19-9)、CA_(242)联合检测  

Detection of serum tumor markers CA_( 19-9),CA_ 242in patients with gastric carcinoma

作　　者：王怀志[1] 郭漳生[2] 赵玉亭[1] 赵国强[1] 

机构地区：[1]武警河南总队医院外一科,郑州450052 [2]郑州大学基础医学院人体解剖学教研室,郑州450052

出　　处：《郑州大学学报（医学版）》2005年第1期98-99,共2页Journal of Zhengzhou University(Medical Sciences)

摘　　要：　　　目的:探讨血清CA19 9、CA242联合检测在胃癌诊断中的作用。方法:采用放射免疫法,对 20例胃良性疾病患者及 31例胃癌患者血清中CA19 9、CA242进行检测。结果:胃癌患者血清CA19 9、CA242的阳性率分别为 38. 71%、48. 39%,高于胃良性疾病组,差异有统计学意义(P<0. 01),联合测定的灵敏度为 74%,特异度为 90%,且对Ⅲ、Ⅳ期胃癌的敏感度和特异度高于Ⅰ、Ⅱ期胃癌(P<0. 01)。结论:CA19 9、CA242联合测定对胃癌有一定的诊断价值,可作为胃良恶性疾病的鉴别标准之一。Aim: To investigate the value of allied measurement of CA 19-9 and CA 242 in serum for patients with gastric carcinoma.Methods: The serum levels of CA 19-9 and CA 242 were measured in 20 cases of benign diseases of stomach and 31 cases of gastric cancer by radioimmunoassay.Results: The positive rates of CA 19-9 and CA 242 in patients with gastric cancer were higher than those in cases of benign disease(P<0.01). The sensitivity of allied measurement was 74%,the specificity was 90%,which were higher in patients at Ⅲ and Ⅳ stage than those at Ⅰ and Ⅱstage(P<0.01).Conclusion: The allied measurement of CA19-9 and CA 242 could become one of the differential criteria for benign and malignant gastric diseases.

关 键 词：胃肿瘤 血清 CA19-9 CA242 

分 类 号：R735[医药卫生—肿瘤]